News

Air Canada announced the start of a $16-million project to expand and enhance Air Canada Cargo’s cold chain handling capabilities for shipments such as pharmaceuticals, fresh food and other perishables at its Toronto Pearson International Airport cargo facility. The...

There are many variables to consider for adeno-associated virus (AAV) upstream bioprocess development. These may include cell line selection and development, plasmid construction, growth mode (suspension versus adherent), transfection type and conditions, production phase, media type, and harvest methods....

Responding to the emerging challenge of rapid vaccine production and global distribution is at the forefront to ending the global COVID-19 pandemic. With various vaccine candidates currently in clinical trials, manufacturers are scaling-up their single-use production facilities to address the...

uMotif, a leading eClinical platform provider powering patient-centric research, announced a reorganisation of its leadership structure as Steve Rosenberg is appointed CEO. The announcement forms part of a wider evolution of uMotif’s executive team, with Julia Lakeland also joining...

AstraZeneca’s Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus (SLE), a serious autoimmune disease, who show insufficient response to currently available treatment. The approval by the Japanese Ministry of Health, Labour...

Recent positive interim results of Sanofi’s mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going...

Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody. “This partnership has the potential to significantly expand and maximize the axatilimab program...